New drug could ease bulging eyes in thyroid disease

NCT ID NCT07257185

Recruiting now Disease control Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests an injection called MHB018A for people with chronic moderate-to-severe thyroid eye disease. The drug targets a protein linked to inflammation and eye bulging. About 150 adults will receive either the drug or a placebo every 4 weeks for 6 months. The main goal is to see if the drug reduces eye bulging by at least 2 millimeters.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MHB018A (a humanized antibody targeting IGF-1 receptor)
What this could lead to: If it works, this could provide a new treatment option to reduce eye bulging and inflammation in people with chronic thyroid eye disease.
What could go wrong: This is a Phase 3 trial, but results are not yet known. The drug may not work better than placebo, and side effects are possible. It is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE, TED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endocrine exophthalmos Graves Ophthalmopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYROID EYE DISEASE, TED

Contacts and locations

Locations

Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, 201419, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.